Summary
AbbVie Inc. (ABBV) filed this Form 8-K on November 7, 2019, to provide important financial information related to its proposed acquisition of Allergan plc. The filing includes Allergan's unaudited consolidated financial statements for the three and nine months ended September 30, 2019 and 2018, offering investors a look at Allergan's recent performance prior to the integration. Furthermore, AbbVie presented unaudited pro forma condensed combined financial information. This information illustrates how the combined entity might look financially, including a pro forma balance sheet as of September 30, 2019, and pro forma statements of earnings for the year ended December 31, 2018, and the nine months ended September 30, 2019. This pro forma data is crucial for investors to understand the potential scale and financial profile of the combined company post-acquisition, though it is presented for informational purposes and not as a definitive forecast.
Key Highlights
- 1AbbVie is providing financial information on Allergan in anticipation of their acquisition.
- 2Included are Allergan's unaudited consolidated financial statements for Q3 and YTD periods ending September 30, 2019 and 2018.
- 3AbbVie has also filed unaudited pro forma condensed combined financial information to show potential post-acquisition financial standing.
- 4The pro forma data includes a balance sheet as of September 30, 2019, and income statements for the year 2018 and YTD 2019.
- 5This information is presented to aid investor understanding of the potential combined entity.
- 6The filing emphasizes that the pro forma information is for informational purposes and not a guarantee of future results.
- 7The report also contains forward-looking statements regarding the acquisition and its potential impacts.